Inhibitory effect of dietary monoglucosylceramide 1-O-β-glucosyl-N-2′-hydroxyarachidoyl-4,8-sphingadienine on two different categories of colon preneoplastic lesions induced by 1,2-dimethylhydrazine in F344 rats

Cancer Science

Volumn 96, Issue 12, 2005, Pages 876-881

  Inamine, Morihiko ^a   Suzui, Masumi ^a   Morioka, Takamitsu ^a   Kinjo, Tatsuya ^a   Kaneshiro, Tatsuya ^a   Sugishita, Tomoko ^b   Okada, Tadashi ^b   Yoshimi, Naoki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b 1 Numata Kitagata cho   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; BETA CATENIN; CYCLINE; MONOGLUCOSYLCERAMIDE 1 O BETA GLUCOSYL N 2' HYDROXYARACHIDOYL 4,8 SPHINGADIENINE; SPHINGOLIPID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; COLON CARCINOGENESIS; COLON MUCOSA; COLON TUMOR; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG ISOLATION; DRUG STRUCTURE; INTESTINE CRYPT; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RAT; RAT STRAIN; RICE BRAN;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; COLONIC NEOPLASMS; DIET; GLUCOSYLCERAMIDES; MALE; ORYZA SATIVA; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; SPHINGOLIPIDS;

EID: 30344488721     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00127.x     Document Type: Article

References (35)

1. Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH Jr. Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 1999; 129: 1239-50.
2. Merrill AH Jr, Schmelz EM, Dillehay DL et al. Sphingolipids - the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 1997; 142: 208-25.
3. Spiegel S, Merrill AH Jr. Sphingolipid metabolism and cell growth regulation. FASEB J 1996; 10: 1388-97.
4. Zeisel SH, Char D, Sheard NF. Choline, phosphatidylcholine and sphingomyelin in human and bovine milk and infant formulas. J Nutr 1986; 116: 50-8.
5. Fujino Y, Ohnishi M, Ito S. Molecular species of ceramide and mono-, di-, tri-, and tetraglycosylceramide in bran and endosperm of rice grains. Agric Biol Chem 1985; 49: 2753-62.
6. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002; 110: 3-8.
7. Schmelz EM, Merrill AH Jr. Ceramides and ceramide metabolites in cell regulation: evidence for dietary sphingolipids as inhibitors of colon carcinogenesis. Nutrition 1998; 14: 717-19.
8. Schmelz EM, Sullards MC, Dillehay DL, Merrill AH Jr. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1,2-dimethythydrazine-treated CF1 mice. J Nutr 2000; 130: 522-7.
9. Schmelz EM, Dillehay DL, Webb SK, Reiter A, Adams J, Merrill AH Jr. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 1996; 56: 4936-41.
10. Schmelz EM, Bushnev AS, Dillehay DL, Liotta DC, Merrill AH Jr. Suppression of aberrant colonic crypt foci by synthetic sphingomyclins with saturated or unsaturated sphingoid base backbones. Nutr Cancer 1997; 28: 81-5.
11. Lemonnier LA, Dillehay DL, Vespremi MJ, Abrams J, Brody E, Schmelz EM. Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch Biochem Biophys 2003; 419: 129-38.
12. Symolon H, Schmelz EM, Dillehay DL, Merrill AH Jr. Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethythydrazine-treated CF1 mice and ApcMin/+ mice. J Nutr 2004; 134: 1157-61.
13. Dillehay DL, Webb SK, Schmelz EM, Merrill AH Jr. Dietary sphingomyelin inhibits 1,2-dimediylhydrazine-induced colon cancer in CF1 mice. J Nutr 1994; 124: 615-20.
14. Stevens VL, Winton EF, Smith EE, Owens NE, Kinkade JM Jr, Merrill AH Jr. Differential effects of long-chain (sphingoid) bases on the monocytic differentiation of human leukemia (HL-60) cells induced by phorbol esters, 1 alpha, 25-dihydroxyvitamin D3, or ganglioside GM3. Cancer Res 1989; 49: 3229-34.
15. Ahn EH, Schroeder JJ. Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp Biol Med (Maywood) 2002; 227: 345-53.
16. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995; 93: 55-71.
17. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43: 1-21.
18. Pretlow TP, Barrow BJ, Ashton WS et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51: 1564-7.
19. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22: 287-94.
20. Roncucci L. Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma. Ital J Gastroenterol 1992; 24: 498-501.
21. Jen J, Powell SM, Papadopoulos N et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54: 5523-6.
22. Yamada Y, Yoshimi N, Hirose Y et al. Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000; 60: 3323-7.
23. Yamada Y, Yoshimi N, Hirose Y et al. Sequential analysis of morphological and biological properties of beta-catenin-accumnlated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001; 61: 1874-8.
24. Hirose Y, Kuno T, Yamada Y et al. Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003; 24: 107-11.
25. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37: 147-51.
26. Nabandith V, Suzui M, Morioka T et al. Inhibitory effects of crude alpha-mangostin, a xanthone derivative, on two different categories of colon preneoplastic lesions induced by 1,2-dimethylhydrazine in the rat. Asian Pac J Cancer Prev 2004; 5: 433-8.
27. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57: 1301-5.
28. Suzui M, Inamine M, Kaneshiro T et al. Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int J Oncol 2005; 27: 1391-9.
29. Kohno H, Tanaka T, Kawabata K et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002; 101: 461-8.
30. Tanaka T. Chemoprevention of human cancer: biology and therapy. Crit Rev Oncol Hematol 1997; 25: 139-74.
31. Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill AH Jr. Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 1994; 124: 702-12.
32. Merrill AH Jr, Sweeley CC. Sphingoid Metabolism and Cell Signaling, 2nd edn. Amsterdam: Elsevier Science Publishers, 1996.
33. Schmelz EM, Roberts PC, Kustin EM et al. Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 2001; 61: 6723-9.
34. Suzui M, Ushijima T, Dashwood RH et al. Frequent mutations of the rat beta-catenin gene in colon cancers induced by methylazoxymethanol acetate plus 1-hydroxyanthraquinone. Mol Carcinog 1999; 24: 232-7.
35. Dashwood RH, Suzui M, Nakagama H, Sugimura T, Nagao M. High frequency of beta-catenin (ctnnb 1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. Cancer Res 1998; 58: 1127-9.